Clinical Trial Update: A Study of JNJ-54767414 (HuMax CD38) (Anti-CD38 Monoclonal Antibody) in Combination With Backbone Treatments for the Treatment of Patients With Multiple Myeloma [Phase 1]

View source ↗

Summary

Phase 1 study evaluating JNJ-54767414 (HuMax CD38) in combination with backbone therapies for multiple myeloma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• HuMax CD38 (JNJ-54767414)

Snippet

Sponsor: Janssen Research & Development, LLC | Conditions: Multiple Myeloma | Phase 1 | Status: COMPLETED